Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + oxaliplatin + irinotecan
- Development stage
- Unknown
- Lead developer
- Mount Sinai Beth Israel
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
CAPOXIRI is an investigational neoadjuvant chemotherapy combination consisting of capecitabine, oxaliplatin, and irinotecan. Developed and evaluated by Beth Israel Medical Center, this regimen is primarily indicated for patients with resectable, borderline resectable, or locally advanced pancreatic adenocarcinoma. The combination aims to enhance the efficacy of standard treatments like FOLFIRINOX by utilizing the oral fluoropyrimidine capecitabine as a substitute for infusional 5-fluorouracil. Capecitabine acts as a prodrug of 5-fluorouracil, which inhibits thymidylate synthase to disrupt DNA synthesis. Oxaliplatin is a platinum-based agent that forms intra- and inter-strand DNA cross-links, while irinotecan inhibits DNA topoisomerase I, preventing the religation of DNA strands. Together, these agents provide a multi-targeted approach to induce apoptosis and inhibit tumor growth in pancreatic cancer.
- Other names
- CAPOXIRI regimenNeoadjuvant CAPOXIRI
02
Targets
TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on capecitabine + oxaliplatin + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + oxaliplatin + irinotecan.